Analyst Jonathan Wolleben of JMP Securities reiterated a Buy rating on Madrigal Pharmaceuticals (MDGL – Research Report), with a price target ...

Madrigal Pharmaceuticals, Inc. (NASDAQ:MDGL – Get Free Report) has been given an average rating of “Moderate Buy” by the thirteen ratings firms that are presently covering the stock, Marketbeat.com ...

Madrigal Pharmaceuticals, Inc. (Nasdaq: MDGL) today announced that the Company will present at the 43 rd Annual J.P. Morgan Healthcare Conference on Wednesday, January 15, 2025 at 2:15 pm PT. The ...

Madrigal Pharmaceuticals' strong launch is confirmed with impressive sales in Q1 and Q2. Learn why MDGL stock could benefit ...

Madrigal Pharmaceuticals, Inc. (Nasdaq: MDGL) announced that it will present at the 43rd Annual J.P. Morgan Healthcare ...

Madrigal Pharma has become the first drugmaker to claim FDA approval for a drug to treat metabolic dysfunction-associated steatohepatitis (MASH), an elusive target that has seen many other ...

Madrigal Pharmaceuticals (NASDAQ:MDGL) rose 2% in after hours trading amid some takeover speculation. There's speculation that Madrigal (MDGL) may have attracted interest from a large ...

Madrigal said that all patients enrolled in MAESTRO-NASH - which include up to 2,000 in total - are continuing on therapy after the initial 52-week treatment period.

Liver Cirrhosis Therapies and Key Companies .Resmetirom: Madrigal Pharmaceuticals Inc. .Key Liver Cirrhosis Companies: Madrigal Pharmaceuticals Inc., Galectin Therapeutics, Akero Therapeutics ...

The lawsuit led to state and national reforms. By Michael S. Rosenwald Dolores Madrigal, the lead plaintiff in a landmark lawsuit brought by Latina women in California who said they were coerced ...

Significant stake increases in Madrigal Pharma, now the largest position at ~28% of the portfolio, and Tellurian Inc. Key holdings such as Perpetua Resources, BrightSphere Investment Group ...